Profile
| Metric | Value |
|---|---|
| Full Name | Genmab A/S |
| Ticker | NASDAQ: GMAB |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | Denmark |
| IPO | |
| Indexes | Not included |
| Website | genmab.com |
| Employees | 2,638 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $35.34 | |
| Price, 1D Change | +4.34% | |
| Market Cap | $22B | |
| - | ||
| PE Ratio | 15.01 | |
| Beta | 0.53 | |
| Revenue | $3B | |
| Revenue, 1Y Change | +30.60% | |
| EPS | $1.76 | |
| EPS, 1Y Change | +83.72% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | 5:1 | |
| Next Split | N/A | N/A |
| Last Ticker Change | GMXAY | |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | $1.76 | |
| EPS Estimate | $1.92 | |
| EPS Est. Change | +8.83% | |
| Revenue | $3.12B | |
| Revenue Estimate | $23.71B | |
| Revenue Est. Change | +659.55% | |
| Current Price | $35.34 | |
| Price Target | - | $38.00 |
| Price Tgt. Change | - | +7.53% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $12.27 | $0.96 | -92.19% | |
| $1.25 | $1.76 | +40.74% | |
| $1.92 | N/A | +8.83% | |
| $1.52 | N/A | -13.92% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $2.38B | $2.39B | +0.35% | |
| $21.29B | $3.12B | -85.34% | |
| $23.71B | N/A | +659.55% | |
| $27.40B | N/A | +777.76% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +63.31% | |
| Price, 3Y | -12.00% | |
| Market Cap, 1Y | +58.07% | |
| Market Cap, 3Y | -17.24% | |
| Revenue, 1Y | +30.60% | |
| Revenue, 3Y | +131.57% | |
| EPS, 1Y | +83.72% | |
| EPS, 3Y | +143.16% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $35.34 | |
| SMA 200 | $25.74 | |
| SMA 200 vs Price | -27.16% | |
| SMA 50 | $31.56 | |
| SMA 50 vs Price | -10.70% | |
| Beta | 0.53 | |
| ATR | $0.86 | |
| 14-Day RSI | 67.11 | |
| 10-Day Volatility | 36.72% | |
| 1-Year Volatility | 37.42% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $3.12B | |
| EPS | $1.76 | |
| Gross Profit | $2.92B | |
| Gross Margin | 93.51% | |
| Operating Profit | $1.02B | |
| Operating Margin | 32.53% | |
| Net Income | $1.14B | |
| Net Margin | 36.44% | |
| EBITDA | $1.08B |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.03 | |
| Current Ratio | 5.25 | |
| Quick Ratio | 5.24 | |
| - | ||
| F-Score | 7 | |
| Altman Z-Score | 12.63 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | 15.01 | |
| PS Ratio | 6.05 | |
| PB Ratio | 3.78 | |
| EV/EBITDA | 13.28 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $5.10B | |
| Cash & Equivalents | $2.93B | |
| Total Assets | $6.36B | |
| Current Assets | $3.87B | |
| Total Liabilities | $1.27B | |
| Current Liabilities | $737.06M | |
| Total Debt | $142.88M | |
| Short Term Debt | $12.77M | |
| Accounts Payable | $483.50M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $1.98B | |
| Operating Expenses | $1.90B | |
| Cost Of Goods Sold | $202.74M | |
| SG&A | $0.00 | |
| D&A | $59.89M | |
| Interest Expense | $0.00 | |
| Income Tax | $191.43M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | $1.13B | |
| CFI | -$1.44B | |
| CFF | -$568.34M | |
| Capex | $44.09M | |
| Free Cash Flow | $1.08B |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| HC Wainwright & Co. | → | |
| Truist Securities | → | |
| HC Wainwright & Co. | → | |
| HC Wainwright & Co. | → | |
| Guggenheim | → | |
| Guggenheim | → | |
| HC Wainwright & Co. | → | |
| Truist Securities | → | |
| HC Wainwright & Co. | → | |
| HC Wainwright & Co. | → |
Analyst sentiment
Institutional ownership
Screeners with GMAB
Data Sources & References
- GMAB Official Website www.genmab.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1434265/000143426525000092/0001434265-25-000092-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1434265/000155837025000846/0001558370-25-000846-index.htm
- GMAB Profile on Yahoo Finance finance.yahoo.com/quote/GMAB
- GMAB Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/gmab
FAQ
What is the ticker symbol for Genmab A/S?
The ticker symbol for Genmab A/S is NASDAQ:GMAB
Does Genmab A/S pay dividends?
No, Genmab A/S does not pay dividends
What sector is Genmab A/S in?
Genmab A/S is in the Healthcare sector
What industry is Genmab A/S in?
Genmab A/S is in the Biotechnology industry
What country is Genmab A/S based in?
Genmab A/S is headquartered in Denmark
When did Genmab A/S go public?
Genmab A/S initial public offering (IPO) was on June 1, 2009
Is Genmab A/S in the S&P 500?
No, Genmab A/S is not included in the S&P 500 index
Is Genmab A/S in the NASDAQ 100?
No, Genmab A/S is not included in the NASDAQ 100 index
Is Genmab A/S in the Dow Jones?
No, Genmab A/S is not included in the Dow Jones index
When was Genmab A/S last earnings report?
Genmab A/S's most recent earnings report was on November 6, 2025
When does Genmab A/S report earnings?
The next expected earnings date for Genmab A/S is February 17, 2026